Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03830125
Recruitment Status : Completed
First Posted : February 5, 2019
Last Update Posted : January 18, 2020
Sponsor:
Collaborator:
KCRN Research, LLC
Information provided by (Responsible Party):
Bridge Biotherapeutics, Inc.

Brief Summary:
This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Drug: BBT-877, Single dose Drug: Placebo group Drug: BBT-877, Multiple doses Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult Subjects
Actual Study Start Date : February 13, 2019
Actual Primary Completion Date : November 24, 2019
Actual Study Completion Date : November 24, 2019


Arm Intervention/treatment
Experimental: Single Ascending Doses Drug: BBT-877, Single dose
Single dose of BBT-877, 5 dose levels, oral capsule

Drug: Placebo group
Placebo matched to BBT-877, oral capsule

Experimental: Multiple Ascending Doses Drug: Placebo group
Placebo matched to BBT-877, oral capsule

Drug: BBT-877, Multiple doses
Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule




Primary Outcome Measures :
  1. The number and severity of treatment emergent adverse events (TEAEs) [ Time Frame: 7 days after the last dose ]
    To assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.


Secondary Outcome Measures :
  1. Peak Plasma Concentration of BBT-877 in plasma [ Time Frame: 72 hours after the last dose ]
    The PK of BBT-877

  2. Area under the plasma concentration versus time curve of BBT-877 in plasma [ Time Frame: 72 hours after the last dose ]
    The PK of BBT-877

  3. Peak Plasma Concentration of BBT-877 in plasma under fed condition. [ Time Frame: 72 hours after the last dose ]
    The food effect on the PK of a single dose of BBT-877

  4. Area under the plasma concentration versus time curve of BBT-877 in plasma under fed condition. [ Time Frame: 72 hours after the last dose ]
    The food effect on the PK of a single dose of BBT-877

  5. Raw and change-from-baseline values of plasma LPAs [ Time Frame: 72 hours after the last dose ]
    To assess the PD of BBT-877 by assessment of plasma LPAs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult male and/or female (non-childbearing potential only), 19 to 55 years of age, inclusive, at screening.
  • Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dose and throughout the study.
  • BMI ≥ 18.5 and ≤ 32.0 kg/m2 and weight ≥ 50 kg at screening.
  • Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, as deemed by the PI or designee.
  • No clinically significant history or presence of ECG findings as judged by the PI or qualified designee at screening and check-in.
  • For a female, must be of non-childbearing potential and therefore must have undergone one of the following sterilization procedures, at least 6 months prior to the first dose:

    1. hysteroscopic sterilization;
    2. bilateral tubal ligation or bilateral salpingectomy;
    3. hysterectomy;
    4. bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.
  • A non-vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study drug. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to the first dose of study drug. A male who has been vasectomized less than 4 months prior to the first dose must follow the same restrictions as a non-vasectomized male).
  • If male, must agree to not donate sperm from the first dose until 90 days after the last dose of study drug.
  • Must have the ability to understand and sign a written informed consent form (ICF), which must be obtained prior to initiation of study procedures.

Exclusion Criteria:

  • Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  • History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  • History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose or regular alcohol consumption within 6 months prior to the first dose with an average weekly intake of greater than 21 glasses/units per week for males or 14 glasses/units per week for females, with one unit = 150 mL of wine or 360 mL of beer or 45 mL of 45% alcohol.
  • History or presence of hypersensitivity or idiosyncratic reaction to the study drug(s) or related compounds.
  • History of anemia or history of decreased red blood cells (RBC).
  • Estimated creatinine clearance <80 mL/min at screening.
  • Liver function tests (serum ALT, AST, alkaline phosphatase) and serum bilirubin (total and direct) > ULN.
  • Baseline hemoglobin, hematocrit, RBC < lower limit of normal at screening and Day -1.
  • Female subjects who are pregnant or who are lactating.
  • Positive urine drug or alcohol results at screening or check-in.
  • Positive urine cotinine at screening.
  • Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).
  • Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning approximately 14 days prior to the first dose and throughout the study. Hormone replacement therapy will not be allowed. After first dosing, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee.
    • Any drugs known to be significant inducers of CYP3A enzymes and/or P-glycoprotein, including St. John's Wort, for 28 days prior to the first dosing and throughout the study. Appropriate sources (e.g., Flockhart Table) will be consulted to confirm lack of PK/PD interaction with study drug.
  • Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 28 days prior to the first dose and throughout the study.
  • Donation of blood or significant blood loss within 56 days prior to the first dose.
  • Plasma donation within 7 days prior to the first dose.
  • Exposure to more than four new chemical entities within 12 months prior to first dosing day.
  • The subject has participated in a clinical trial and has received an investigational product within 30 days, or 5 half-lives of the investigational product (whichever is longer) of the first dose of study drug in the current study.
  • Any condition or circumstance, in the opinion of the PI or designee, which may make the subject unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the subject's safety.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03830125


Locations
Layout table for location information
United States, Nebraska
Celerion
Lincoln, Nebraska, United States, 68502
Sponsors and Collaborators
Bridge Biotherapeutics, Inc.
KCRN Research, LLC
Investigators
Layout table for investigator information
Study Director: Jeong-Hyun Ryou, M.D., Ph.D. Bridge Biotherapeutics, Inc.

Layout table for additonal information
Responsible Party: Bridge Biotherapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03830125    
Other Study ID Numbers: BBT877-IPF-001
First Posted: February 5, 2019    Key Record Dates
Last Update Posted: January 18, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bridge Biotherapeutics, Inc.:
Autotaxin
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Lung Diseases
Respiratory Tract Diseases
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial